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In November 2012, a 72-year old patient was diagnosed with left eye wet age-
related macular degeneration. The patient received three monthly intravitreal injections
of ranibizumab, with complete resolution of retinal hemorrhage and edema and
reinstatement of visual acuity. In May 2015, symptomatic relapse was detected. The
patient was again treated with intravitreal ranibizumab, with overall six injections till
the end of February 2016. In May 2016, the patient complained of left hand resting
tremor, bradykinesia, and postural rigidity of head and trunk. A diagnosis of clinically
established PD was made based on new criteria of the Movement Disorders Society.
Single Photon Emission Computerized Tomography of the Dopamine Transporter with
(123I) ioflupane documented a low Dopamine Transporter (DAT) uptake mostly in the
right striatum. Due to the documented protective role of vascular endothelial growth
factor (VEGF) on the dopaminergic neurons, intensive intravitreal injections of the anti-
VEGF agent ranibizumab may have played as an additional risk factor accelerating the
neurodegeneration process related to PD and the onset of the related clinical signs and
symptoms.
Keywords: anti-vascular endothelial growth factors, ranibizumab, Parkinson’s disease, intravitreal,
neurodegeneration
INTRODUCTION
Age-related macular degeneration (AMD) is a chronic progressive disorder of the retina,
representing the main cause of irreversible vision loss in elderly people (de Jong, 2006) in both
Western and Eastern Countries.
The neovascular or “wet” AMD is characterized by choroidal neovascularization and vascular
leakage, associated with up-regulation of angiogenic factors, such as vascular endothelial growth
factor (VEGF), a cytokine that promotes vascular permeability and angiogenesis. Through
reduction of edema and new blood vessel growth, VEGF inhibitors administered by intravitreal
injection are an established treatment for “wet” AMD and include bevacizumab (only as off-label
use), pegaptanib, and, more recently, ranibizumab and aflibercept.
Recent studies revealed that VEGF displays a key role in neuronal survival and proliferation
(Drake and Little, 1995; Silverman et al., 1999; Storkebaum and Carmeliet, 2004), with
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neuroprotective effects, due to apoptosis inhibition, stimulation
of neurogenesis, and activation of antioxidants (Zachary, 2005;
Krum et al., 2008; Nowacka and Obuchowicz, 2012; Quittet et al.,
2015). This effect has been highlighted also on dopaminergic
(DA) neurons and on both in vitro and in vivo pre-clinical
studies on Parkinson’s disease (PD) models (Yasuhara et al.,
2004, 2005a,b; Yasuda et al., 2007; Falk et al., 2011; Piltonen
et al., 2011; Yue et al., 2014). Inhibition of the neuroprotective
effects associated to VEGF may theoretically play a role in the
development of neurodegenerative disorders involving dopamine
transmission, including PD.
We report a case of PD which occurred after long-term
treatment with intravitreal injections of ranibizumab for the
treatment of wet AMD.
CASE REPORT
In November 2012, a 72-year old man was diagnosed with
wet AMD in his left eye, based on fundus examination and
optical coherence tomography (OCT), which was requested for
the onset of metamorphopsia. At that time, he was treated
with combination of angiotensin converting enzyme inhibitor
plus thiazide diuretic for a 20-year history of well controlled
hypertension.
His best-corrected visual acuity in the right and left eyes
was 10/10 and 8/10, respectively. On slit-lamp examination,
both anterior chambers showed clear aqueous humor and no
inflammatory reaction. Dilated fundus examination revealed a
subretinal whitish mass and adjacent subretinal hemorrhage.
OCT confirmed the presence of a subretinal lesion and
intraretinal edema. After obtaining informed consent, the patient
was monthly treated with intravitreal administration of 0.5 mg
ranibizumab for three months, without any complication and
with complete retinal hemorrhage and edema resolution and
increased visual acuity of left eye (10/10). Thereafter, the patient
underwent routine follow-up visits, on a 2-month basis, including
fundus examination and OCT which did not document any
abnormal finding. In May 2014, a reduction of visual acuity
(from 10/10 to 7/10) was registered. The patient was periodically
followed-up but not treated with anti-VEGF drugs as there
was no sign of neovascularization. In May 2015, visual acuity
further reduced to 3/10 and both fundus examination and OCT
revealed a reactivation of the neovascular membrane, edema and
pigment epithelial detachment. For this reason, the patient was
again treated with intravitreal injections of ranibizumab (0.5 mg),
firstly on a monthly basis and thereafter using treat and extend
approach, with overall six injections till the end of February 2016,
when visual acuity increased to 6/10. At the follow-up visit in May
2016, the neovascular membrane appeared inactive and the visual
acuity was stable at 6/10, so the ophthalmologist decided for a pro
re nata approach (i.e., as needed).
In the same period, the patient referred to the Movement
Disorders Clinic due to intermittent tremor on the left hand,
started around February 2016. He did not complain non-motor
symptoms.
Neurological examination disclosed resting tremor on the left
hand, mild bradykinesia of left lower limb, and mild rigidity of
head and trunk. His motor Unified Parkinson’s Disease Rating
Scale (UPDRS) was 11/108.
The patient had no family history of PD or other
neurodegenerative diseases nor had he been ever exposed to
pesticides. Magnetic Resonance Imaging of the brain showed rare
small subcortical white matters hyperintensities on T2 (mainly
periventricular and frontal) and some bilateral hypointensities in
T1 in the striatum, more prominent on the right, compatible with
small ischemic lesions.
Single Photon Emission Computerized Tomography (SPECT)
of the Dopamine Transporter (DAT) with 123I-ioflupane
documented a significant and clear low uptake of DAT, mostly in
the right striatum (Figure 1). A diagnosis of clinically established
PD was made based on new criteria of the Movement Disorders
Society (Postuma et al., 2015).
A treatment with levodopa/carbidopa (300 mg/daily) was
started at the beginning of 2017, due to worsening of tremor
and bradykinesia leading to gait impairment and fatigue (motor
UPDRS = 15/108). At follow-up examination in May 2017,
response to levodopa was demonstrated by improvement of
FIGURE 1 | (A) Bilateral hypointensities in T1 in the striatum, more prominent on the right side and (B) rare small subcortical white matters hyperintensities on T2
(mainly periventricular and frontal) on Magnetic Resonance Imaging of the brain. (C) Single Photon Emission Computerized Tomography of the Dopamine
Transporter (DAT) with 123I-ioflupane showing a significant low uptake of DAT, mostly in the right striatum.
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motor symptoms (motor UPDRS = 6/108), particularly of gait.
Up to November 2017 other two injections of ranibizumab were
intravitreally administered with visual acuity equal to 3/10 and
the patient was in stable treatment with levodopa/carbidopa
(300 mg/daily).
DISCUSSION
We described the development of PD in a patient without any
genetic and environmental risk factor for PD, who received
repeated intravitreal injections of ranibizumab for wet AMD
over the previous year. The clinical picture with lack of atypical
features is consistent with the clinical diagnosis of PD. The
DAT SPECT evidence of pre-synaptic dopamine loss supports
the presence of neurodegeneration in the nigro-striatal pathway,
typical of neurodegenerative Parkinsonism. Moreover, brain
MRI did not disclose areas of cortical and subcortical atrophy,
suggesting the diagnosis of atypical Parkinsonism. The presence
of vascular lesions in the basal ganglia at brain MRI does
not exclude the diagnosis of idiopathic PD, as they have been
described in PD patients with vascular risk factors, such as
hypertension (Antonini et al., 2012). On the other hand, there is
a strong biological plausibility and temporal relationship between
intensive intravitreal administration of ranibizumab and onset of
PD-related signs and symptoms which may suggest a role of the
anti-VEGF drug as additional risk factor resulting potentially in
accelerating the PD-related neurodegeneration process.
PD is a multi-systemic neurodegenerative disease, primarily
affecting DA neurons of substantia nigra, and characterized
by intracellular accumulation of the protein α-synuclein
(Poewe et al., 2017). Mechanisms of neurodegeneration
hypothesized in PD include abnormal α-synuclein degradation
by the ubiquitin–proteasome system and the lysosomal
autophagy system, propagation of α-synuclein with a prion-
like mechanism, mitochondrial dysfunction, oxidative stress,
and neuroinflammation (Poewe et al., 2017). Recent studies
demonstrated in PD patients the presence of α-synuclein in
the retina (Bodis-Wollner et al., 2014) as well the presence
of specific OCT abnormalities, such as reduced parafoveal
thickness (Slotnick et al., 2015). The retina has several molecular
and cellular features in common with the brain, such as
neurons, glial cells, connected vasculature, and a blood barrier
(Trost et al., 2016). The most liable mechanisms potentially
explaining the relationship between AMD and PD are related
to neurodegenerative processes and chronic inflammation: the
activation of microglia cells in the retina and nervous system
may trigger the inflammatory response and aggravate both the
retinal and DA degeneration (Whitton, 2007). Ranibizumab
is a humanized recombinant monoclonal antibody fragment
targeted against human VEGF. It binds with high affinity to
the VEGF-A isoforms, thus preventing binding of VEGF-A
to its receptors (European Medicines Agency. Lucentis –
Summary of Product Characteristics. Available from: http:
//www.ema.europa.eu/docs/en_GB/document_library/EPAR_
-_Product_Information/human/000715/WC500043546.pdf.
Accessed 01 Feb 2018). Ranibizumab maintains effective retinal
concentrations for around 1 month, being able to reach low
concentrations in the serum compartment as well (Stewart,
2012; Gibson and Gibson, 2014). Based on the Summary of
Product Characteristics (European Medicines Agency. Lucentis –
Summary of Product Characteristics. Available from: http:
//www.ema.europa.eu/docs/en_GB/document_library/EPAR_
-_Product_Information/human/000715/WC500043546.pdf.
Accessed 01 Feb 2018), following monthly intravitreal injections
in AMD patients, serum concentrations of ranibizumab generally
range between 0.79 and 2.90 ng/ml. Such concentrations are
below the drug concentration necessary to inhibit the VEGF
activity by 50% (IC50 = 11–27 ng/ml). Serum ranibizumab
concentrations are predicted to be approximately 90,000-fold
lower than vitreal ranibizumab concentrations. Results from
clinical trials documented no significant reduction in serum
VEGF levels within the first 1 month of treatment (Zehetner
et al., 2015), but a significant decline in systemic VEGF levels was
detected after 1 and 2 years (Enders et al., 2015). The resulting
systemic VEGF inhibition after intravitreal injections may lead
to systemic effects (Gibson and Gibson, 2014). Clinical trials
on ranibizumab showed a high incidence of stroke, myocardial
infarction and non-ocular hemorrhage (Brown et al., 2006;
Rosenfeld et al., 2006), further confirmed by recent observational
studies (Kemp et al., 2013; Pratt et al., 2014). Furthermore,
a meta-analysis of randomized trials on ranibizumab for
AMD treatment identified a stronger relationship of systemic
vascular adverse events and intravitreal administration of VEGF
inhibitors in case of more intensive treatment schedule (Ueta
et al., 2014).
Recent evidence suggested that the VEGF signal pathway
may directly and indirectly improve DA neuron survival
(Silverman et al., 1999; Pitzer et al., 2003; Yasuhara et al.,
2004). VEGF administration inhibits DA neurons loss in PD
models, especially in the substantia nigra and in the striatum
(Sheikh et al., 2017), thus representing a potential therapeutic
target for prevention of DA neuron death and PD progression.
Functional polymorphisms of the VEGF gene expression have
been associated with an increased risk of developing PD in the
Chinese Ham population (Wu et al., 2016). It has been postulated
that reduced VEGF levels may cause neurodegeneration, by
impairing neural tissue perfusion, thus causing ischemia and
production of free radicals (Storkebaum and Carmeliet, 2004).
This hypothesis is consistent with a recent autopsy study
in patients with dementia with Lewy body, in whom VEGF
deficiency has been associated with a loss of microvessels and
low occipital blood flow (Miners et al., 2014). On the other
hand, VEGF is up-regulated by ischemic and inflammatory
stimulation, which accompany neurodegeneration. The state of
brain hypoxia up-regulates VEGF and its subsequent higher
levels mediate angiogenesis, causing microvascular leakage and
fragility. These changes lead to edema, bleeding, and impair
neural tissue perfusion. The resultant hypoxia then further up-
regulate VEGF levels again (Storkebaum and Carmeliet, 2004).
VEGF shows neuroprotective effects, due to apoptosis
inhibition, stimulation of neurogenesis, and activation of
antioxidants (Zachary, 2005; Krum et al., 2008; Nowacka and
Obuchowicz, 2012; Quittet et al., 2015). Specifically, ranibizumab
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binds to the VEGF-A, one of the five isoforms of the VEGF family
and one of the strongest inducers of vascular permeability (Yla-
Herttuala et al., 2007), which showed neuroprotective effects in
several in vitro and in vivo PD models (Silverman et al., 1999;
Pitzer et al., 2003; Yasuhara et al., 2004; Tian et al., 2007; Yue et al.,
2014). A recent study on the Italian ADR Spontaneous Reporting
System showed 3 reports of “extrapyramidal syndrome” due
to intravitreal bevacizumab and 1 to intravitreal aflibercept
(Cutroneo et al., 2017). Similarly, in the Food and Drug
Administration’s Adverse Event Reporting System, three cases
of neurodegenerative disorders have been reported following
bevacizumab use (Shamloo et al., 2012). On the other hand, the
onset of such disorders may be due to vascular events and/or
stroke, which are well known and listed risks of intravitreal
therapy with anti-VEGF drugs in general, including ranibizumab.
Finally, a meta-analysis of randomized trials on ranibizumab for
AMD treatment identified a stronger relationship of systemic
vascular adverse events and intravitreal administration of VEGF
inhibitors in case of more intensive treatment schedule (Ueta
et al., 2014).
All the above described experimental and epidemiological
evidence raise the hypothesis that persistent and intensive VEGF
inhibition concurred to DA degeneration in our patient. AMD
may be considered as a neurodegeneration of the retina (de
Jong, 2006), thus potentially sharing with PD common biological
pathways, such as oxidative stress and inflammation (Ding et al.,
2009; Poewe et al., 2017). Chung et al. (2014) investigated
the risk of developing PD within 3 years after the AMD
diagnosis in a retrospective cohort, population-based, claims
database study in Taiwan . Adjusting for several vascular risk
factors (i.e., coronary heart disease, hypertension, diabetes, and
hyperlipidemia), subjects with AMD had a significant higher
risk of developing PD than AMD-free patients during follow-
up. On the contrary, a case-control study found no statistically
significant differences in the frequency of AMD between patients
with idiopathic PD and healthy subjects (Nowacka et al., 2014).
Using claims databases from the United States, Brilliant et al.
(2016) found that around 70% of the levodopa users started
the drug treatment after AMD diagnosis . However, the use of
anti-VEGF drugs, which are on the market since 2005, was not
considered in any of the studies and it cannot be excluded that
anti-VEGF drugs rather than AMD itself triggered the clinical
manifestation of PD.
CONCLUSION
In conclusion, our case report points out to VEGF inhibition
as a possible additional risk factor of neurodegeneration of DA
neurons in PD.
According to the Naranjo causality assessment scale (Naranjo
et al., 1981), the causal relationship between use of ranibizumab
and PD development was scored as “possible”.
In particular, we hypothesize that long-term treatment
with intravitreal ranibizumab led to a persistent inhibition
of VEGF activity which played an important compensatory
neuroprotective role in older patient with AMD, ultimately
triggering PD.
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